Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
June 05, 2023 07:48 ET
|
Walden Biosciences, Inc.
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 CAMBRIDGE,...
Walden Biosciences Announces Participation at October Investor Conferences
October 13, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Participation in Citi’s 17th Annual BioPharma Conference
August 31, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
August 24, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
July 26, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...
Unicycive Reports Key Findings from Market Research with Nephrologists
July 20, 2022 07:12 ET
|
Unicycive Therapeutics, Inc.
Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...
OPEN MINDS Community Members, PsychU.org & PKDnetwork.org, Partner To Provide A Webinar Addressing Major Depressive Disorder In Chronic Kidney Disease
December 03, 2019 10:01 ET
|
Open Minds
Gettysburg, Pa, Dec. 03, 2019 (GLOBE NEWSWIRE) -- PsychU.org and PKDnetwork.org have joined forces to provide a cutting edge webinar that will address the mental health challenges of Major...